R&D channel feed – Endpoints News

R&D channel feed

Biohaven’s protein degrader is promising in early IgAN trial, heads straight to Phase 3

5 months ago

AbbVie partners with Simcere Pharma unit to develop myeloma drug

5 months ago

Hengrui and Kailera’s injected incretin posts best-in-class obesity data in Phase 2 trial

5 months ago

Gilead taps into STAT6 space via $250M deal with Leo Pharma

5 months ago

Regor’s obesity pill posts muted weight loss in Phase 2a, enters new trial

5 months ago

Bayer’s BlueRock now plans to bring Parkinson’s cell therapy straight to Phase 3 trial

5 months ago

Pfizer touts bladder cancer results as first advancement for some patients 'in decades'

6 months ago

Dyne details pivotal plans for myotonic dystrophy RNA drug, though data blip worries some investors

6 months ago

Repare pauses late-stage plans, reshuffles pipeline in effort to cut costs

6 months ago

Marea reports early Phase 2 data for cholesterol-lowering drug it licensed from Novartis

6 months ago

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

6 months ago

Bayer says elinzanetant quelled hot flashes in women undergoing cancer treatment

6 months ago

Tenpoint reveals positive Phase 3 data for vision drug after Visus merger

6 months ago

Aiolos team reunites with $411M for new biotech with obesity drugs from China

6 months ago

MaaT Pharma touts ‘unprecedented’ Phase 3 efficacy of graft-versus-host disease treatment

6 months ago

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

6 months ago

Pfizer, GSK add risk of Guillain-Barré to RSV vaccine labels at FDA's request

6 months ago

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

6 months ago

‘Too elegant to ignore’: Novo-allied Aspect Biosystems nabs $115M for bioprinted tissue therapies

6 months ago

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

6 months ago

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

6 months ago

With schizophrenia trial success, LB Pharmaceuticals thinks about Phase 3 and next funding

6 months ago

Jasper reports more data in spontaneous hives from tiny study

6 months ago

Calico, Denali's ALS drugs miss primary objectives in basket study

6 months ago

First page Previous page 16 17 181920 21 22 Next page Last page